News List

Emergex Awarded \"Innovate UK\" Grant to progress its universal and pandemic Flu vaccine


Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announced that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.

By Team ABLE

Emergex bags funding from UK Innovate. This grant will cover 70 percent of the cost of developing Emergex’s flu vaccine programme over a period of two years. It will be used to complete preclinical toxicology and validation studies and the manufacturing of the vaccine in accordance with current Good Manufacturing Practice (cGMP). This will result in clinical batches of the vaccine which are ready for Phase I clinical testing in the first half of 2020.

Emergex’s universal flu vaccine is designed to target components of the influenza virus that are common to all influenza strains. As a result this vaccine will also be suitable to target the outbreak of a new flu pandemic caused by the emergence of a novel form of influenza virus at the time it moves from an animal species into humans. The company’s vaccine is 100% synthetic and delivers highly conserved immunogenic peptide fragments from the flu virus to antigen presenting cells in the skin, eliciting a strong and long-lasting T-cell immune response.

Emergex’s vaccine combines several proprietary technologies to create an immune response based on ‘reverse engineering’. This involves the identification of highly conserved internal peptide fragments from the flu virus, synthesis of these peptide fragments to create a library of 100% synthetic peptide fragments and screening these against blood from flu survivors to see which of the fragments elicit the strongest T-cell immune response. The selected peptide fragments are then combined with a gold nanotechnology carrier system to make an extremely small particle, less than 5 nanometres in diameter, which is ideal for immunization through the skin using a microneedle skin patch, which is less invasive than traditional injection.

The UK government risk register has identified pandemic flu as one of one of the most severe natural challenges likely to affect the UK over the next few years1. A recent World Health Organization model predicts that pandemic flu could kill an estimated 720,000 people per year and result in economic losses of over US$500bn2.

Professor Thomas Rademacher, co-founder, CEO and CSO at Emergex commented, “This Innovate UK grant provides endorsement of our flu vaccine programme and reinforces our belief that an innovative approach, using the very latest technologies, could help protect the public from this inevitable epidemic or pandemic health threat.”

In addition to developing a universal flu vaccine, Emergex is also developing a universal Flavivirus vaccine which is cross reactive against Zika, Dengue and Yellow Fever, and a universal Filovirus vaccine which is cross reactive against Ebola and Marburg virus.